Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

Sage Therapeutics SAGE announced that its board ... In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%. Earlier this month, Biogen made an acquisition ...

The firm owned 18,246 shares of the biopharmaceutical company’s stock after selling 21,172 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Sage Therapeutics were ...

Sage Therapeutics has a unique approach to targeting ... This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...